Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2020

View Archived Issues

Base editing gives temporary hearing fix

Nuclear quality control by chaperones

Sensorion reports preclinical findings on otoferlin gene therapy program

FDA clears IND application for first-in-class monoclonal anti-VISTA antibody, C-I8993

Interim phase I data for ONCOS-102 plus durvalumab in peritoneal malignancies

First-in-human data presented for ALT-P7 in advanced HER2-positive breast cancer

Modified peptides generate RA-specific CD4+ T cells with lytic properties against APCs

First connection between an ARSD gene variant and disease identified

Dana-Farber Cancer Institute and Voronoi patent DYRK1A inhibitors

U.K. researchers present BCL-6 inhibitors

Roche synthesizes new MGL inhibitors

Exon-intron fusions play role in osteosarcoma metastases

Merck & Co. describes new adenosine receptor antagonists

Novartis presents new PCSK9 inhibitors

New preclinical data presented on bispecific antibody ALG.APV-527 for solid tumors

AbbVie reports new phase IIa data on ABBV-3373 in moderate to severe rheumatoid arthritis

Cleave begins phase I study of CB-5339 in relapsed/refractory AML and MDS

BioCryst reports data from Zika virus study of galidesivir in primate model

Phase III trial of INP-104 for acute migraine meets primary objectives

Phase I/IIa trial studies Turnstone's TBio-6517 in solid tumors

Actuate Therapeutics begins pediatric phase I study of 9-ING-41 for refractory malignancies

Domain Therapeutics' biased PAR2 inhibitors show antiarthritic effects

Regeneron initiates first clinical trial of REGN-COV2 antibody cocktail for COVID-19

Dosing begins in phase I study of BBP-418 for limb girdle muscular dystrophy type 2i

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...